Science & Innovation

Pipeline

Dorzagliatin

mGluR5

Poster and Presentation

Peer Reviewed Publications

Announcements and Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock Information

Corporate Communications

Portfolio Advisory Board

Senior Scientific Advisory Board

Media

Company News

Nov 08

2019

Hua Medicine to Release Phase III 24-Weeks Topline Data of Dorzagliatin Monotherapy Trial (HMM0301) on November 12

Hua Medicine (HKEX: 2552), a Shanghai-based drug development company focused on developing a global first-in-class oral drug for the treatment of type 2 diabetes, today announced that 24-week topline data of dorzagliatin’s monotherapy trial (HMM0301) will be released on November 12, 2019, and management will present the results and answer any questions via conference call.

Aug 30

2019

Hua Medicine completes patient enrollment for Phase III combination with metformin trial of dorzagliatin

Aug 16

2019

Hua Medicine Announces 2019 Interim Results

Hua Medicine ("Hua"or the"Company", Stock Code: 2552.HK), as a pre-revenue drug development company, today announced its interim results for the six months ended June 30, 2019 (the"Review Period").

Jun 20

2019

Hua Medicine – Recap of ADA 79th Scientific Sessions

At last week's American Diabetes Association's 79th Scientific Sessions, Hua Medicine, a Shanghai-based drug development company focused on developing a global first-in-class oral drug for the treatment of Type 2 diabetes, presented data from an enzyme kinetics study differentiating dorzagliatin from other glucokinase activators, and preliminary data on unbiased machine learning clustering analysis.

Jun 05

2019

Hua Medicine – Business & Pipeline Update

Hua Medicine (HKEX: 2552), announced today our updated pipeline regarding our core technology targeting glucose homeostasis and first product, a glucokinase activator dorzagliatin (HMS5552).

Apr 23

2019

Hua Medicine Initiates First Combination Study of Dorzagliatin with SGLT-2 in the United States

Hua Medicine (HKEX: 2552), a Shanghai-based drug development company focused on developing a global first-in-class oral drug for the treatment of Type 2 diabetes, announced today dosing of the first patient in a Phase I drug-drug interaction trial of HMS5552 (dorzagliatin) in patients with insufficiently controlled T2D with metformin, DPP-4 inhibitor, or SGLT2 inhibitor, alone or in combination therapy (metformin plus DPP-4 inhibitor, or metformin plus SGLT-2 inhibitor).

Mar 08

2019

Hua Medicine Announces 2018 Annual Results

Hua Medicine (the"Company", Stock Code: 2552.HK) today announced its consolidated results for the year ended December 31, 2018 (the"Review Period").

Mar 01

2019

Hua Medicine completes patient enrollment for Phase III monotherapy trial of dorzagliatin

Feb 11

2019

Hua Medicine Appoints Dr. Ralph Anthony DeFronzo as Distinguished Scientific Consultant

Hua Medicine (HKEX: 2552), a Shanghai-based drug development company focused on developing a global first-in-class oral drug for the treatment of Type 2 diabetes, announced the appointment of Dr. Ralph Anthony DeFronzo as Global Consultant – Distinguished Scientific Consultant of the Company.

About Us

Company Overview

Company History

Leadership Team

Portfolio Advisory Board

Senior Scientific Advisory Board

Partner

Media center

Research & Development

Inovation

Pipeline

Dorzagliatin

mGluR5

Company Publications

Peer Reviewed Publications

Investor Relations

Corporate Governance

Financial Report

Announcements & Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock information

Media

Company News

Media Releases

Video

Careers

Culture

Join Us

Product

HuaTangNing(华堂宁®)

Focus Us

沪公网安备 31011502013809号 Privacy Statement Terms of Use

How we use cookies

Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.